Literature DB >> 29610748

Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Xu Han1, Marvin T Nieman1.   

Abstract

Entities:  

Year:  2018        PMID： 29610748      PMCID： PMC5879510          DOI： 10.21037/atm.2017.11.36

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Vorapaxar: targeting a novel antiplatelet pathway.

Authors:  Younos Abdulsattar; Theologia Ternas; Danielle Garcia
Journal:  P T       Date:  2011-09

2.  YD-3, a novel inhibitor of protease-induced platelet activation.

Authors:  C C Wu; S W Huang; T L Hwang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  Aspirin as an antiplatelet drug.

Authors:  C Patrono
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

4.  Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.

Authors:  Kayla J Temple; Matthew T Duvernay; Jae G Maeng; Anna L Blobaum; Shaun R Stauffer; Heidi E Hamm; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-10-11       Impact factor: 2.823

5.  Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex.

Authors:  Wei Zhang; Wei Deng; Liang Zhou; Yan Xu; Wenjun Yang; Xin Liang; Yizhen Wang; John D Kulman; X Frank Zhang; Renhao Li
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

Review 6.  Platelet receptors and signaling in the dynamics of thrombus formation.

Authors:  José Rivera; María Luisa Lozano; Leyre Navarro-Núñez; Vicente Vicente
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

7.  Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds.

Authors:  T Nishi; F Tabusa; T Tanaka; T Shimizu; T Kanbe; Y Kimura; K Nakagawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-04       Impact factor: 1.645

8.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

9.  Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets.

Authors:  Summer E Young; Matthew T Duvernay; Michael L Schulte; Craig W Lindsley; Heidi E Hamm
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

10.  High-resolution crystal structure of human protease-activated receptor 1.

Authors:  Cheng Zhang; Yoga Srinivasan; Daniel H Arlow; Juan Jose Fung; Daniel Palmer; Yaowu Zheng; Hillary F Green; Anjali Pandey; Ron O Dror; David E Shaw; William I Weis; Shaun R Coughlin; Brian K Kobilka
Journal:  Nature       Date:  2012-12-09       Impact factor: 49.962
View more
  1 in total

1.  Sex-Specific Platelet Activation Through Protease-Activated Receptors Reverses in Myocardial Infarction.

Authors:  Beom Soo Kim; David S Auerbach; Hamza Sadhra; Matthew Godwin; Rohan Bhandari; Frederick S Ling; Amy Mohan; David I Yule; Larry Wagner; David Q Rich; Sara Ture; Craig N Morrell; Livia Timpanaro-Perrotta; Arwa Younis; Ilan Goldenberg; Scott J Cameron
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-11-12       Impact factor: 8.311
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.